Company / R&D Expense
Boston Scientific R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$2.1B
FY2025
5-year range
$1.2B / $2.1B
FY2021-FY2025
Trend
+27.1%
vs FY2024
Sector context
#3 of 110
Health Care
What the data says
Among 110 Health Care companies, Boston Scientific is in the top 3% for r&d expense. R&D Expense has increased for 5 consecutive years, from $1.1B in FY2020 to $2.1B in FY2025.
Based on SEC 10-K filings.
$2.1B in FY2025 with a 5-year CAGR of +13.0%. Ranks 3rd among 110 companies in Health Care.
Improved from $1.4B to $2.1B over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +15.8%
- 5-Year CAGR
- +13.0%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 110This company $2.1B Sector average $298.2M
▼
+588.2% above sector average
Key checks
Key Insights
- Boston Scientific's r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +13.0%, indicating consistent growth.
- In FY2025, r&d expense increased 27.1% year-over-year.
- Ranks #3 out of 110 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.1B | +27.1% |
| FY2024 | $1.6B | +14.2% |
| FY2023 | $1.4B | +6.9% |
| FY2022 | $1.3B | +12.7% |
| FY2021 | $1.2B | +5.5% |
| FY2020 | $1.1B | -5.2% |
| FY2019 | $1.2B | +5.5% |
| FY2018 | $1.1B | +11.6% |
| FY2017 | $997.0M | +8.4% |
| FY2016 | $920.0M | +5.0% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026